Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.
The increase in patient awareness and the longer life expectancies are driving the growth of the Chinese diabetes market. There is potentially great opportunity for multinational pharmaceutical companies seeking to penetrate the antidiabetic therapies market in China. However, many drugs that are launched in the West, such as SGLT-2 inhibitors and long-acting release GLP-1 analogues, are not yet available in China, and the most recently launched DPP-IV inhibitors and short-acting GLP-1 analogues are still optimizing uptake in this highly lucrative market. Navigating the road to reimbursement and optimizing market access are, therefore, challenging.
This Emerging Markets Physician & Payer Forum report explores the market access opportunities and obstacles that will impact the treatment of type 2 diabetes in China in the next two to three years.
Markets covered: China.
Primary research: This report draws on insights from surveyed 50 physicians (31 endocrinologists/ diabetologists and 19 primary care physicians), as well as interviews with payers who influence pricing and reimbursement decisions.. Payers come from the following backgrounds: Advisor, Ministry of Human Resources and Social Security (MOHRSS), Beijing; Advisor, Endocrine Medical Association, Qiqihar; Advisor, China Food and Drug Administration (CFDA), Beijing.
Epidemiology: Prevalence of diabetes.
Emerging therapies: Phase III: 5 drugs; preregistration: 2 drugs.
Already a Client? Log in to access this report.